Literature DB >> 9925390

MR cholangiography: technical advances and clinical applications.

A S Fulcher1, M A Turner, G W Capps.   

Abstract

Magnetic resonance (MR) cholangiography is a fast, accurate, noninvasive alternative to endoscopic retrograde cholangiography (ERC) in the evaluation of biliary tract disease. Technical improvements in imaging sequences (eg, half-Fourier rapid acquisition with relaxation enhancement) and use of phased-array coils allow high-quality imaging comparable to that available with ERC. In choledocholithiasis, common bile duct stones as small as 2 mm can be detected with MR cholangiography and appear as low-signal-intensity foci within the high-signal-intensity bile. MR cholangiography may help establish the diagnosis of malignant obstruction and is useful in the evaluation of patients in whom ERC was unsuccessful or incomplete. The role of MR cholangiography in the evaluation of intrahepatic duct disease continues to evolve. MR cholangiography plays a crucial role in evaluating postsurgical biliary tract alterations and can be used to demonstrate a variety of congenital anomalies of the biliary tract (eg, aberrant ducts, choledochal cysts, pancreas divisum). In addition, intentional or incidental imaging of the gallbladder with MR cholangiography can be used to identify calculi or help determine the presence and extent of neoplastic disease.

Entities:  

Mesh:

Year:  1999        PMID: 9925390     DOI: 10.1148/radiographics.19.1.g99ja0525

Source DB:  PubMed          Journal:  Radiographics        ISSN: 0271-5333            Impact factor:   5.333


  17 in total

Review 1.  CT and MR cholangiography: advantages and pitfalls in perioperative evaluation of biliary tree.

Authors:  T Hyodo; S Kumano; F Kushihata; M Okada; M Hirata; T Tsuda; Y Takada; T Mochizuki; T Murakami
Journal:  Br J Radiol       Date:  2012-03-14       Impact factor: 3.039

Review 2.  [Value of radiological methods in the diagnosis of biliary diseases].

Authors:  J E W Zajaczek; M Keberle
Journal:  Radiologe       Date:  2005-11       Impact factor: 0.635

3.  Update of PET and PET/CT for hepatobiliary and pancreatic malignancies.

Authors:  Dominique Delbeke; William H Martin
Journal:  HPB (Oxford)       Date:  2005       Impact factor: 3.647

4.  Comparison of different MRCP techniques for the depiction of biliary complications after liver transplantation.

Authors:  Sonja Kinner; Alexander Dechêne; Susanne C Ladd; Thomas Zöpf; Evelin Maldonado de Dechêne; Guido Gerken; Thomas C Lauenstein
Journal:  Eur Radiol       Date:  2010-02-16       Impact factor: 5.315

5.  Low conjunction of the cystic duct with the common bile duct: does it correlate with the formation of common bile duct stones?

Authors:  I Tsitouridis; G Lazaraki; C Papastergiou; E Pagalos; G Germanidis
Journal:  Surg Endosc       Date:  2006-09-06       Impact factor: 4.584

6.  Water imaging (hydrography) in the fetus: the value of a heavily T2-weighted sequence.

Authors:  Beth M Kline-Fath; Maria A Calvo-Garcia; Sara M O'Hara; Judy M Racadio
Journal:  Pediatr Radiol       Date:  2006-11-29

Review 7.  [Inflammatory diseases of the gall bladder and biliary system. II. Acute and chronic inflammation of the biliary system--primary biliary cirrhosis].

Authors:  H Helmberger; B Kammer
Journal:  Radiologe       Date:  2005-06       Impact factor: 0.635

Review 8.  Magnetic resonance cholangiopancreatography: a useful tool in the evaluation of pancreatic and biliary disorders.

Authors:  Ahmet-Mesrur Halefoglu
Journal:  World J Gastroenterol       Date:  2007-05-14       Impact factor: 5.742

9.  Evaluation of the biliary and pancreatic system with 2D SSFSE, breathhold 3D FRFSE and respiratory-triggered 3D FRFSE sequences.

Authors:  S Palmucci; L A Mauro; M Coppolino; A G Musumeci; P V Foti; P Milone; G C Ettorre
Journal:  Radiol Med       Date:  2010-01-15       Impact factor: 3.469

10.  Is preoperative histological diagnosis necessary before referral to major surgery for cholangiocarcinoma?

Authors:  E Buc; M Lesurtel; J Belghiti
Journal:  HPB (Oxford)       Date:  2008       Impact factor: 3.647

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.